Analysis reveals mixed outcomes for Bristol-Myers Squibb (BMY). Decline in earnings is forecasted, shareholders from investments made three years ago are in red. New appointments, including Cristian Massacesi, M.D. as EVP, CMO, and Head of Development, and Cari Gallman as Executive VP, General Counsel and Chief Policy Officer have been noted. Investment expert Jim Cramer offers a faint pulse evaluation. Positive developments include outperforming the broader market, promising Phase 3 studies for KarXT (Bipolar-I Disorder) and Deucravacitinib (Sjögren’s Syndrome) targeted drugs. However, shares have seen a slide and Morgan Stanley maintains a sell rating. Another drug, BMS-986419, is currently under investigation and exciting Phase 3 results are noted. The company also plans $2 billion in cost cuts by 2027.With over 81% ownership from strong institutional backers, the company has strong support. However, a looming patent cliff is identified as a concern. Notwithstanding the challenges, BMY presents as a good long-term dividend stock, and its Q1 and future outlook exceeded expectations.
Bristol-Myers Squibb BMY News Analytics from Thu, 06 Feb 2025 08:00:00 GMT to Fri, 25 Jul 2025 20:57:31 GMT - Rating -4 - Innovation 6 - Information 8 - Rumor 0
